

Control and Population Sciences, 9609 Medical Center Drive, 3E438, MSC 9764, Rockville, MD, 20850 or call non-toll-free number 240-276-6806 or Email your request, including your address to: [janet.demoor@nih.gov](mailto:janet.demoor@nih.gov). Formal requests for additional plans and instruments must be requested in writing.

**Comment Due Date:** Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

**Proposed Collection:** The National Physician Survey of Precision Medicine in Cancer Treatment 0925-NEW, National Cancer Institute (NCI), National Institutes of Health (NIH).

**Need and Use of Information Collection:** The purpose of this study is to investigate the current practice of

precision medicine in cancer treatment among medical oncologists in the U.S. This is a nationally representative survey designed to assess oncologists' current and potential use of genomic testing, to inform the development of interventions to facilitate optimal use of genomic testing and to improve patient-physician discussions of the risks, possible benefits, and uncertainties surrounding the use of these tests. Current knowledge of this topic is limited as there are no nationally-representative studies on this topic to date. There are only two non-federal studies two that have examined physicians' knowledge and attitudes regarding somatic genetic and genomic testing. The survey will be administered by mail and web to approximately 1,630 oncology physicians across the U.S.

Non-respondents will be invited to complete a follow-back survey to share their reasons for not participating. The study findings will inform NCI of relevant issues and concerns relating to the application of precision medicine to current and future cancer treatment patterns and practice. This information will also inform the development of new funding initiatives to optimize the use of precision medicine in cancer treatment. Additionally, information collected as part of this survey will be used to develop physician educational materials to address barriers to precision medicine in cancer care delivery.

OMB approval is requested for 2 years. There are no costs to respondents other than their time. The total estimated annualized burden hours are 261.

**ESTIMATED ANNUALIZED BURDEN HOURS**

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Total annual burden hour
Precision Medicine Survey—Pilot Study.	Oncology Physicians .....	175	1	20/60	58
Precision Medicine Survey—Full Study.	Oncology Physicians .....	600	1	20/60	200
Follow-back Survey .....	Oncology Physicians .....	40	1	5/60	3

Dated: October 28, 2015.

**Karla Bailey,**

*Project Clearance Liaison, NCI, NIH.*

[FR Doc. 2015-29382 Filed 11-17-15; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Innovation for HIV Vaccine Discovery (R01).

**Date:** December 10-11, 2015.

**Time:** 11:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, Room 3G61, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

**Contact Person:** Jane K. Battles, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room # 3F30B, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20852-9823, (240) 669-5029, [battlesja@mail.nih.gov](mailto:battlesja@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: November 12, 2015.

**Natasha Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015-29380 Filed 11-17-15; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Drug Abuse Amended; Notice of Meeting**

Notice is hereby given of a change in the meeting of the National Institute on Drug Abuse Special Emphasis Panel, November 13, 2015, 01:00 p.m. to November 13, 2015, 05:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD, 20852 which was published in the **Federal Register** on October 22, 2015, 80 FR 64428.

The date of the meeting was changed to December 1, 2015. The meeting is closed to the public.

Dated: November 12, 2015.

**Natasha Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2015-29379 Filed 11-17-15; 8:45 am]

**BILLING CODE 4140-01-P**